5-HT_2A receptor

The 5-HT_2A receptor is a subtype of the 5-HT₂ receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR).[4] The 5-HT_2A receptor is a cell surface receptor.[5] 5-HT is short for 5-hydroxy-tryptamine, which is serotonin. This is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT_2A may also have an inhibitory effect[6] on certain areas such as the visual cortex and the orbitofrontal cortex.[7] This receptor was first noted for its importance as a target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. Later it came back to prominence because it was also found to be mediating, at least partly, the action of many antipsychotic drugs, especially the atypical ones.

HTR2A
Identifiers
Aliases	HTR2A, 5-HT2A, HTR2, 5-hydroxytryptamine receptor 2A
External IDs	OMIM: 182135 MGI: 109521 HomoloGene: 68073 GeneCards: HTR2A
Gene location (Human) Chr. Chromosome 13 (human)[1] Band 13q14.2 Start 46,831,550 bp[1] End 46,897,076 bp[1]
RNA expression pattern More reference expression data
Gene ontology Molecular function • 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding • G-protein coupled receptor activity • virus receptor activity • signal transducer activity • drug binding • G-protein alpha-subunit binding • G-protein coupled serotonin receptor activity • serotonin binding • neurotransmitter receptor activity • GO:0001948 protein binding • GO:0032403 macromolecular complex binding Cellular component • cytoplasm • integral component of membrane • cytosol • cell projection • membrane • cell body fiber • integral component of plasma membrane • dendritic shaft • axon • neuronal cell body • caveola • cytoplasmic vesicle • cell membrane • dendrite • glutamatergic synapse • integral component of postsynaptic membrane • integral component of presynaptic membrane Biological process • detection of mechanical stimulus involved in sensory perception of pain • release of sequestered calcium ion into cytosol • regulation of dopamine secretion • phospholipase C-activating serotonin receptor signaling pathway • urinary bladder smooth muscle contraction • positive regulation of MAP kinase activity • behavioral response to cocaine • positive regulation of cytosolic calcium ion concentration • positive regulation of kinase activity • positive regulation of phosphatidylinositol biosynthetic process • aging • cellular calcium ion homeostasis • cell death • memory • activation of phospholipase C activity • detection of temperature stimulus involved in sensory perception of pain • protein localization to cytoskeleton • sleep • positive regulation of vasoconstriction • positive regulation of cell proliferation • negative regulation of potassium ion transport • positive regulation of ERK1 and ERK2 cascade • artery smooth muscle contraction • positive regulation of peptidyl-tyrosine phosphorylation • viral entry • phosphatidylinositol 3-kinase signaling • nociception • temperature homeostasis • GO:0022415 viral process • positive regulation of fat cell differentiation • positive regulation of glycolytic process • negative regulation of synaptic transmission, glutamatergic • signal transduction • chemical synaptic transmission • response to drug • serotonin receptor signaling pathway • phospholipase C-activating G-protein coupled receptor signaling pathway • G-protein coupled receptor signaling pathway • animal behavior • regulation of synaptic vesicle exocytosis • G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	3356	15558
Ensembl	ENSG00000102468	ENSMUSG00000034997
UniProt	P28223	P35363
RefSeq (mRNA)	NM_001165947 NM_000621 NM_001378924	NM_172812
RefSeq (protein)	NP_000612 NP_001159419 NP_001365853	NP_766400
Location (UCSC)	Chr 13: 46.83 – 46.9 Mb	n/a
PubMed search	[2]	[3]
Wikidata
View/Edit Human View/Edit Mouse

Downregulation of post-synaptic 5-HT_2A receptor is an adaptive process provoked by chronic administration of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. Suicidal and otherwise depressed patients have had more 5-HT_2A receptors than normal patients. These findings suggest that post-synaptic 5-HT_2A overdensity is involved in the pathogenesis of depression.[8]

Paradoxical down-regulation of 5-HT_2A receptors can be observed with several 5-HT_2A antagonists.[9] Thus, instead of tolerance, reverse-tolerance would be expected from 5-HT_2A antagonists. However, there is at least one antagonist at this site which has been shown to up-regulate 5-HT_2A receptors.[9][10] Additionally, a couple of other antagonists may have no effect on 5-HT_2A receptor number.[11] Nevertheless, upregulation is the exception rather than the rule. Neither tolerance nor rebound is observed in humans with regard to the SWS promoting effects of 5-HT_2A antagonists.[12]

History

5-HT receptors were split into two classes by John Gaddum and Picarelli when it was discovered that some of the serotonin-induced changes in the gut could be blocked by morphine, while the remainder of the response was inhibited by dibenzyline, leading to the naming of M and D receptors, respectively. 5-HT_2A is thought to correspond to what was originally described as D subtype of 5-HT receptors by Gaddum and Picarelli.[13] In the era before molecular cloning, when radioligand binding and displacement was the only major tool, spiperone and LSD were shown to label two different 5-HT receptors, and neither of them displaced morphine, leading to naming of the 5-HT₁, 5-HT₂ and 5-HT₃ receptors, corresponding to high affinity sites from LSD, spiperone and morphine, respectively.[14] Later it was shown that the 5-HT₂ was very close to 5-HT_1C and thus were grouped together, renaming the 5-HT₂ into 5-HT_2A. Thus, the 5-HT₂ receptor family is composed of three separate molecular entities: the 5-HT_2A (formerly known as 5-HT₂ or D), the 5-HT_2B (formerly known as 5-HT_2F) and the 5-HT_2C (formerly known as 5-HT_1C) receptors.[15]

Distribution

5-HT_2A is expressed widely throughout the central nervous system (CNS). It is expressed near most of the serotonergic terminal rich areas, including neocortex (mainly prefrontal, parietal, and somatosensory cortex) and the olfactory tubercle. Especially high concentrations of this receptor on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, working memory, and attention[16][17][18] by enhancing glutamate release followed by a complex range of interactions with the 5-HT_1A,[19] GABA_A,[20] adenosine A₁,[21] AMPA,[22] mGluR_2/3,[23] mGlu5,[24] and OX₂ receptors.[25][26] In the rat cerebellum, the protein has also been found in the Golgi cells of the granular layer,[27] and in the Purkinje cells.[28][29]

In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system. Additionally, 5-HT_2A mRNA expression has been observed in human monocytes.[30] Whole-body distribution of the 5-HT2A/2C receptor agonist, [11C]Cimbi-36 show uptake in several internal organs and brown adipose tissue (BAT), but it is not clear if this represents specific 5-HT2A receptor binding.[31]

Signaling cascade

The 5-HT_2A receptor is known primarily to couple to the Gα_q signal transduction pathway. Upon receptor stimulation with agonist, Gα_q and β-γ subunits dissociate to initiate downstream effector pathways. Gα_q stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca²⁺ release.[32]

Effects

Physiological processes mediated by the receptor include:

• CNS: neuronal excitation, hallucinations, out-of-body experiences, and fear. Most likely responsible for the psychedelic effects associated with 5-HT_2A receptor agonists such as LSD, DMT, etc.[33][34]
• Activation of the 5-HT_2A receptor with 2,5-dimethoxy-4-iodoamphetamine (DOI) produces potent anti-inflammatory effects in several tissues including cardiovascular and gut. Other 5-HT_2A agonists like LSD also have potent anti-inflammatory effects against TNF-alpha-induced inflammation.[35][36]
• Activation of the 5-HT_2A receptor in hypothalamus causes increases in hormonal levels of oxytocin, prolactin, ACTH, corticosterone, and renin.[37][38]
• Role in memory and learning[18][39][40]
• Role in arthralgia.[41][42]
• Role in Alzheimer's disease.[43]
• Smooth muscle contraction in the gut.[5]
• Probable role in sleep paralysis.[34]

Ligands

Agonists

Activation of the 5-HT_2A receptor is necessary for the effects of the "classic" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT_2A agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched.[44][45] Agonists acting at 5-HT_2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Newer findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT_2A–mGlu2 and not by monomeric 5-HT_2A receptors.[46][47][33] Agonists enhance dopamine in PFC,[18] enhance memory and play an active role in attention and learning.[48][49]

Full agonists

• 25I-NBOH and its 2-methoxy-analog 25I-NBOMe[50]
• ¹⁸F FECIMBI-36, radiolabelled agonist ligand for mapping 5-HT_2A / 5-HT_2C receptor distribution[51]
• TCB-2[52]
• Mexamine is a full agonist to several serotonin receptors.
• O-4310, 5-HT_2A selective, claimed to have 100x selectivity over 5-HT_2C and be inactive at 5-HT_2B
• PHA-57378, dual 5-HT_2A / 5-HT_2C agonist, anxiolytic effects in animal studies.[53]
• 25B-NBOMe Also known as Cimbi-36; used as a PET imaging tool for visualizing the 5-HT_2A receptor[54]

Partial agonists

• 25C-NBOMe
• 25CN-NBOH, 100x selectivity for 5-HT_2A over 5-HT_2C, 46x selectivity over 5-HT_2B.[55]
• Bromo-DragonFLY[56]
• (R)-DOI, traditionally the most common 5-HT_2A reference agonist used in research[57]
• Efavirenz, an antiretroviral drug, produces psychiatric side effects thought to be mediated by 5-HT_2A.[58]
• Juncosamine, is a structurally constrained derivative of 25B-NBOMe, which acts as a potent partial agonist with 124x selectivity for 5-HT_2A over 5-HT_2C, making it the most selective agonist ligand identified to date.[59]
• Lisuride, an antiparkinson dopamine agonist of the ergoline class, that is also a dual 5-HT_2A / 5-HT_2C agonist[60] and 5-HT_2B antagonist.[61]
• Mefloquine, an antimalarial drug, also produces psychiatric side effects which may be mediated through 5-HT_2A and/or 5-HT_2C receptors.[62]
• Methysergide, a congener of methylergonovine, used in treatment of migraine blocks 5-HT_2A and 5-HT_2C receptors, but sometimes acts as partial agonist, in some preparations.
• OSU-6162 acts as a partial agonist at both 5-HT_2A and dopamine D₂ receptors
• SN-22, partial agonist at all three 5-HT₂ subtypes
• Some benzazepines and similar compounds related to lorcaserin are potent 5-HT_2A agonists as well as showing action at 5-HT_2C.[63][64][65][66][67]

Peripherally selective agonists

One effect of 5-HT_2A receptor activation is a reduction in intraocular pressure, and so 5-HT_2A agonists can be useful for the treatment of glaucoma. This has led to the development of compounds such as AL-34662 that are hoped to reduce pressure inside the eyes but without crossing the blood–brain barrier and producing hallucinogenic side effects.[68] Animal studies with this compound showed it to be free of hallucinogenic effects at doses up to 30 mg/kg, although several of its more lipophilic analogues did produce the head-twitch response known to be characteristic of hallucinogenic effects in rodents.[69]

Silent antagonists

• Trazodone is a potent 5-HT_2A antagonist, as well as an antagonist on other serotonin receptors.
• Mirtazapine is a 5-HT_2A, 5-HT_2C, and 5-HT₃ antagonist. Mirtazapine also has an antagonistic effect on H₁ histamine receptors. Because of its wide spectrum of serotonergic receptor inhibition, Mirtazapine exhibits an agonistic effect on 5-HT_1A receptors by funneling more serotonin to them. Mirtazapine is used as an antidepressant in patients dealing with insomnia and weight loss.
• Although ergot alkaloids are mostly nonspecific 5-HT receptor antagonists, a few ergot derivatives such as metergoline bind preferentially to members of the 5-HT₂ receptor family.
• The discovery of ketanserin was a landmark in the pharmacology of 5-HT₂ receptors. Ketanserin, though capable of blocking 5-HT induced platelet adhesion, however does not mediate its well-known antihypertensive action through 5-HT₂ receptor family, but through its high affinity for alpha₁ adrenergic receptors. It also has high affinity for H₁ histaminergic receptors equal to that at 5-HT_2A receptors. Compounds chemically related to ketanserin such as ritanserin are more selective 5-HT_2A receptor antagonists with low affinity for alpha-adrenergic receptors. However, ritanserin, like most other 5-HT_2A receptor antagonists, also potently inhibits 5-HT_2C receptors.
• Nefazodone operates by blocking post-synaptic serotonin type-2A receptors and to a lesser extent by inhibiting pre-synaptic serotonin and norepinephrine (noradrenaline) reuptake.
• Atypical antipsychotic drugs like Lumateperone clozapine, olanzapine, quetiapine, risperidone and asenapine are relatively potent antagonists of 5-HT_2A as are some of the lower potency old generation/typical antipsychotics. Other antagonists are MDL-100,907 (prototype of another new series of 5-HT_2A antagonists) and cyproheptadine.
• Pizotifen is a non-selective antagonist.[70]
• LY-367,265 - dual 5-HT_2A antagonist / SSRI with antidepressant effects
• 2-alkyl-4-aryl-tetrahydro-pyrimido-azepines are subtype selective antagonists (35g: 60-fold).[71]
• AMDA and related derivatives are another family of selective 5-HT_2A antagonists.[72][73][74][75][76]
• Typical antipsychotics such as Haloperidol and Chlorpromazine
• Hydroxyzine (Atarax)
• 5-MeO-NBpBrT
• Niaprazine

Inverse agonists

• AC-90179 - potent and selective inverse agonist at 5-HT_2A, also 5-HT_2C antagonist.[77][78]
• Nelotanserin (APD-125) - selective 5-HT_2A inverse agonist developed by Arena Pharmaceuticals for the treatment of insomnia. APD-125 was shown to be effective and well tolerated in clinical trials.[79]
• Eplivanserin (Sanofi Aventis), a sleeping pill that reached phase II trials (but for which the application for approval was withdrawn), acts as a selective 5-HT_2A inverse agonist.
• Pimavanserin (ACP-103) – more selective than AC-90179, orally active, antipsychotic in vivo, now FDA approved for the treatment of hallucinations and delusions associated with Parkinson's disease.[80][81][82][83][84]
• Volinanserin
• M100907 - Highly selective inverse agonist, >100 fold selectivity over other 5-HT receptors [85]

Functional selectivity

5-HT_2A-receptor ligands may differentially activate the transductional pathways (see above). Studies evaluated the activation of two effectors, PLC and PLA2, by means of their second messengers. Compounds displaying more pronounced functional selectivity are 2,5-DMA and 2C-N. The former induces IP accumulation without activating the PLA2 mediated response, while the latter elicits AA release without activating the PLC mediated response.[86]

Recent research has suggested potential signaling differences within the somatosensory cortex between 5-HT_2A agonists that produce headshakes in the mouse and those that do not, such as lisuride, as these agents are also non-hallucinogenic in humans despite being active 5-HT_2A agonists.[87][88] One known example of differences in signal transduction is between the two 5-HT_2A agonists serotonin and DOI that involves differential recruitment of intracellular proteins called β-arrestins, more specifically arrestin beta 2.[89][90] Cyclopropylmethanamine derivatives such as (-)-19 have also been shown to act as 5-HT_2A/2C agonists with functional selectivity for Gq-mediated signaling compared with β-arrestin recruitment.[91]

Genetics

Chromosome 13.

The 5-HT_2A receptors is coded by the HTR2A gene. In humans the gene is located on chromosome 13. The gene has previously been called just HTR2 until the description of two related genes HTR2B and HTR2C. Several interesting polymorphisms have been identified for HTR2A: A-1438G (rs6311), C102T (rs6313) and His452Tyr (rs6314). Many more polymorphisms exist for the gene. A 2006 paper listed 255.[92][56]

Probable role in fibromyalgia as the T102C polymorphisms of the gene 5HT2A were common in fibromyalgia patients.[93]

Associations with psychiatric disorders

Several studies have seen links between the -1438G/A polymorphism and mood disorders, such as bipolar disorder[94] and major depressive disorder.[95] A weak link with an odds ratio of 1.3 has been found between the T102C polymorphism and schizophrenia.[96] This polymorphism has also been studied in relation to suicide attempts, with a study finding excess of the C/C genotypes among the suicide attempters.[97] A number of other studies were devoted to finding an association of the gene with schizophrenia, with diverging results.[98]

These individual studies may, however, not give a full picture: A review from 2007 looking at the effect of different SNPs reported in separate studies stated that "genetic association studies [of HTR2A gene variants with psychiatric disorders] report conflicting and generally negative results" with no involvement, small or a not replicated role for the genetic variant of the gene.[99]

Treatment response

Genetics seems also to be associated to some extent with the amount of adverse events in treatment of major depression disorder.[100]

Methods to analyse the receptor

The receptor can be analysed by neuroimaging, radioligand, genetic analysis, measurements of ion flows, and in other ways.

Neuroimaging

The 5-HT_2A receptors may be imaged with PET-scanners using the fluorine-18-altanserin,[101] MDL 100,907[102] or [¹¹C]Cimbi-36[54][103] radioligands that binds to the neuroreceptor, e.g., one study reported a reduced binding of altanserin particularly in the hippocampus in patients with major depressive disorder.[104]

Altanserin uptake decreases with age reflecting a loss of specific 5-HT_2A receptors with age.[105][106][107]

Other

Western blot with an affinity-purified antibody and examination of 5-HT2A receptor protein samples by electrophoresis has been described. Immunohistochemical staining of 5-HT2A receptors is also possible.[5]

References

1. GRCh38: Ensembl release 89: ENSG00000102468 - Ensembl, May 2017
2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
3. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal BL (August 1994). "Primary structure of the human platelet serotonin 5-HT_2A receptor: identify with frontal cortex serotonin 5-HT_2A receptor". Journal of Neurochemistry. 63 (2): 465–9. doi:10.1046/j.1471-4159.1994.63020465.x. PMID 8035173. S2CID 40207336.
5. Kling A (2013). 5-HT2A: a serotonin receptor with a possible role in joint diseases (PDF). Umeå: Umeå Universitet. ISBN 978-91-7459-549-9.
6. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML (1998). "Rodent data and general hypothesis: antipsychotic action exerted through 5-HT_2A receptor antagonism is dependent on increased serotonergic tone". Journal of Neural Transmission. 105 (4–5): 365–96. doi:10.1007/s007020050064. PMID 9720968. S2CID 20944107.
7. De Almeida RM, Rosa MM, Santos DM, Saft DM, Benini Q, Miczek KA (May 2006). "5-HT(1B) receptors, ventral orbitofrontal cortex, and aggressive behavior in mice". Psychopharmacology. 185 (4): 441–50. doi:10.1007/s00213-006-0333-3. PMID 16550387. S2CID 33274637.
8. Eison AS, Mullins UL (1996). "Regulation of central 5-HT_2A receptors: a review of in vivo studies". Behavioural Brain Research. 73 (1–2): 177–81. doi:10.1016/0166-4328(96)00092-7. PMID 8788498. S2CID 4048975.
9. Yadav PN, Kroeze WK, Farrell MS, Roth BL (October 2011). "Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 99–105. doi:10.1124/jpet.111.183780. PMC 3186284. PMID 21737536.
10. Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, Le Fur G (January 1993). "Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain". Molecular Pharmacology. 43 (1): 84–9. PMID 8423772.
11. Gray JA, Roth BL (November 2001). "Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists". Brain Research Bulletin. 56 (5): 441–51. doi:10.1016/s0361-9230(01)00623-2. PMID 11750789. S2CID 271925.
12. Vanover KE, Davis RE (28 July 2010). "Role of 5-HT2A receptor antagonists in the treatment of insomnia". Nature and Science of Sleep. 2: 139–50. doi:10.2147/nss.s6849. PMC 3630942. PMID 23616706.
13. Sanders-Bush E, Mayer SE (2006). "Chapter 11: 5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists". In Brunton LL, Lazo JS, Parker K (eds.). Goodman & Gilman's the Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. ISBN 0-07-142280-3.
14. Siegel GJ, Albers RW (2005). Basic neurochemistry: molecular, cellular, and medical aspects. 1 (7th ed.). Academic Press. p. 241. ISBN 0-12-088397-X.
15. Hoyer D, Hannon JP, Martin GR (April 2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology Biochemistry and Behavior. 71 (4): 533–54. doi:10.1016/S0091-3057(01)00746-8. PMID 11888546. S2CID 25543069.
16. Aghajanian GK, Marek GJ (April 1999). "Serotonin, via 5-HT_2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release". Brain Research. 825 (1–2): 161–71. doi:10.1016/S0006-8993(99)01224-X. PMID 10216183. S2CID 20081913.
17. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001). "A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex". Neuroscience. 105 (2): 379–92. doi:10.1016/S0306-4522(01)00199-3. PMID 11672605. S2CID 19764312.
18. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F (December 2005). "The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity". Journal of Neurochemistry. 95 (6): 1597–607. doi:10.1111/j.1471-4159.2005.03485.x. hdl:10261/33026. PMID 16277612. S2CID 18350703.
19. Amargós-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F (March 2004). "Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex". Cerebral Cortex. 14 (3): 281–99. doi:10.1093/cercor/bhg128. PMID 14754868.
20. Feng J, Cai X, Zhao J, Yan Z (September 2001). "Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons". The Journal of Neuroscience. 21 (17): 6502–11. doi:10.1523/JNEUROSCI.21-17-06502.2001. PMC 6763081. PMID 11517239.
21. Marek GJ (June 2009). "Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats". Neuropharmacology. 56 (8): 1082–7. doi:10.1016/j.neuropharm.2009.03.005. PMC 2706691. PMID 19324062.
22. Zhang C, Marek GJ (January 2008). "AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (1): 62–71. doi:10.1016/j.pnpbp.2007.07.009. PMID 17728034. S2CID 44889209.
23. Gewirtz JC, Marek GJ (November 2000). "Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors". Neuropsychopharmacology. 23 (5): 569–76. doi:10.1016/S0893-133X(00)00136-6. PMID 11027922.
24. Marek GJ, Zhang C (September 2008). "Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex". Neuroscience Letters. 442 (3): 239–43. doi:10.1016/j.neulet.2008.06.083. PMC 2677702. PMID 18621097.
25. Lambe EK, Liu RJ, Aghajanian GK (November 2007). "Schizophrenia, hypocretin (orexin), and the thalamocortical activating system". Schizophrenia Bulletin. 33 (6): 1284–90. doi:10.1093/schbul/sbm088. PMC 2779889. PMID 17656637.
26. Liu RJ, Aghajanian GK (January 2008). "Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy". Proceedings of the National Academy of Sciences of the United States of America. 105 (1): 359–64. Bibcode:2008PNAS..105..359L. doi:10.1073/pnas.0706679105. PMC 2224217. PMID 18172209.
27. Geurts FJ, De Schutter E, Timmermans JP (June 2002). "Localization of 5-HT_2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum". Journal of Chemical Neuroanatomy. 24 (1): 65–74. doi:10.1016/S0891-0618(02)00020-0. PMID 12084412. S2CID 16510169.
28. Maeshima T, Shutoh F, Hamada S, Senzaki K, Hamaguchi-Hamada K, Ito R, Okado N (August 1998). "Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells". Neuroscience Letters. 252 (1): 72–4. doi:10.1016/S0304-3940(98)00546-1. PMID 9756362. S2CID 28549709.
29. Maeshima T, Shiga T, Ito R, Okado N (December 2004). "Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum". Neuroscience Research. 50 (4): 411–7. doi:10.1016/j.neures.2004.08.010. PMID 15567478. S2CID 5772490.
30. Dürk T, Panther E, Müller T, Sorichter S, Ferrari D, Pizzirani C, et al. (May 2005). "5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes". International Immunology. 17 (5): 599–606. doi:10.1093/intimm/dxh242. PMID 15802305.
31. Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Knudsen GM, Hansen HD (July 2019). "2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions". EJNMMI Research. 9 (1): 71. doi:10.1186/s13550-019-0527-4. PMC 6669221. PMID 31367837.
32. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (January 2007). "Functional selectivity and classical concepts of quantitative pharmacology". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859. S2CID 447937.
33. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (April 2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neuroscience Letters. 493 (3): 76–9. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.
34. Jalal B (November 2018). "The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug". Psychopharmacology. 235 (11): 3083–3091. doi:10.1007/s00213-018-5042-1. PMC 6208952. PMID 30288594.
35. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–23. doi:10.1124/jpet.108.143461. PMID 18708586. S2CID 25374241.
36. Nau F, Yu B, Martin D, Nichols CD (2013). "Serotonin 5-HT_2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi:10.1371/journal.pone.0075426. PMC 3788795. PMID 24098382.
37. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS (May 2001). "5-HT_2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells". The Journal of Neuroscience. 21 (10): 3572–9. doi:10.1523/JNEUROSCI.21-10-03572.2001. PMC 6762485. PMID 11331386.
38. Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D'Souza DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan K, Petersen BR, Gray TS, Battaglia G, Muma NA, Van de Kar LD (November 2002). "Evidence that 5-HT_2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI". The Journal of Neuroscience. 22 (21): 9635–42. doi:10.1523/JNEUROSCI.22-21-09635.2002. PMC 6758011. PMID 12417689.
39. Harvey JA (2003). "Role of the serotonin 5-HT(2A) receptor in learning". Learning & Memory. 10 (5): 355–62. doi:10.1101/lm.60803. PMC 218001. PMID 14557608.
40. Williams GV, Rao SG, Goldman-Rakic PS, Foresta M, Ropolo M, Degan P, Pettinati I, Kow YW, Damonte G, Poggi A, Frosina G (March 2010). "Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III". Free Radical Biology & Medicine. 48 (5): 681–90. doi:10.1016/j.freeradbiomed.2009.12.007. PMC 6758292. PMID 11923449.
41. Passier A, van Puijenbroek E (2005). "Mirtazapine-induced arthralgia". Br J Clin Pharmacol. 60 (5): 570–2. doi:10.1111/j.1365-2125.2005.02481.x. PMC 1884949. PMID 16236049.
42. Adwan MH (2016). "An update on drug-induced arthritis". Rheumatol Int. 36 (8): 1089–97. doi:10.1007/s00296-016-3462-y. PMID 27000044. S2CID 25401280.
43. Herth MM, Knudsen GM (2015). "Current radiosynthesis strategies for 5-HT2A receptor PET tracers". J Labelled Comp Radiopharm. 58 (7): 265–73. doi:10.1002/jlcr.3288. PMID 25997728.
44. Nichols DE (February 2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.
45. Blaazer AR, Smid P, Kruse CG (September 2008). "Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors". ChemMedChem. 3 (9): 1299–309. doi:10.1002/cmdc.200800133. PMID 18666267. S2CID 7537908.
46. Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, Mocci G, Seto J, Callado LF, Neve RL, Milligan G, Sealfon SC, López-Giménez JF, Meana JJ, Benson DL, González-Maeso J (December 2012). "Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT_2A·mGlu2) receptor heteromerization and its psychoactive behavioral function". The Journal of Biological Chemistry. 287 (53): 44301–19. doi:10.1074/jbc.M112.413161. PMC 3531745. PMID 23129762.
47. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (March 2008). "Identification of a serotonin/glutamate receptor complex implicated in psychosis". Nature. 452 (7183): 93–7. Bibcode:2008Natur.452...93G. doi:10.1038/nature06612. PMC 2743172. PMID 18297054.
48. Wingen M, Kuypers KP, Ramaekers JG (February 2007). "The role of 5-HT1a and 5-HT_2A receptors in attention and motor control: a mechanistic study in healthy volunteers". Psychopharmacology. 190 (3): 391–400. doi:10.1007/s00213-006-0614-x. PMID 17124621. S2CID 25125461.
49. Wingen M, Kuypers KP, Ramaekers JG (July 2007). "Selective verbal and spatial memory impairment after 5-HT1A and 5-HT_2A receptor blockade in healthy volunteers pre-treated with an SSRI". Journal of Psychopharmacology. 21 (5): 477–85. doi:10.1177/0269881106072506. PMID 17092965. S2CID 19575488.
50. Braden MR, Parrish JC, Naylor JC, Nichols DE (December 2006). "Molecular interaction of serotonin 5-HT_2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology. 70 (6): 1956–64. doi:10.1124/mol.106.028720. PMID 17000863. S2CID 15840304.
51. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ, Kumar JS (2017). "In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT_2A/2C receptor PET radioligand in nonhuman primate". Bioorg Med Chem Lett. 27 (1): 21–23. doi:10.1016/j.bmcl.2016.11.043. PMC 5348621. PMID 27889455.
52. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (September 2006). "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT_2A receptor agonists". Journal of Medicinal Chemistry. 49 (19): 5794–803. doi:10.1021/jm060656o. PMID 16970404.
53. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM (July 2003). "2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists". Bioorganic & Medicinal Chemistry Letters. 13 (14): 2369–72. doi:10.1016/S0960-894X(03)00403-7. PMID 12824036.
54. Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, Jørgensen LM, Hansen M, Baandrup AO, Bache S, Svarer C, Kristensen JL, Gillings N, Madsen J, Knudsen GM (July 2014). "Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36". Journal of Cerebral Blood Flow and Metabolism. 34 (7): 1188–96. doi:10.1038/jcbfm.2014.68. PMC 4083382. PMID 24780897.
55. "Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Revised, Duplex print).pdf". Google Docs.
56. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (March 2001). "Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists". Journal of Medicinal Chemistry. 44 (6): 1003–10. doi:10.1021/jm000491y. PMID 11300881.
57. Canal CE, Morgan D (July 2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Testing and Analysis. 4 (7–8): 556–76. doi:10.1002/dta.1333. PMC 3722587. PMID 22517680.
58. Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, Rice KC, France CP, Dillon GH, Forster MJ, Schetz JA (November 2013). "The HIV antiretroviral drug efavirenz has LSD-like properties". Neuropsychopharmacology. 38 (12): 2373–84. doi:10.1038/npp.2013.135. PMC 3799056. PMID 23702798.
59. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT_2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC 3547484. PMID 23336049.
60. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). "Agonist activity of LSD and lisuride at cloned 5HT_2A and 5HT2C receptors". Psychopharmacology. 136 (4): 409–14. doi:10.1007/s002130050585. PMID 9600588. S2CID 3021798.
61. Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). "Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis". Clinical Neuropharmacology. 29 (2): 80–6. doi:10.1097/00002826-200603000-00005. PMID 16614540. S2CID 33849447.
62. Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK (July 2014). "Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro". Psychopharmacology. 231 (14): 2771–83. doi:10.1007/s00213-014-3446-0. PMC 4097020. PMID 24488404.
63. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, et al. (July 2003). "2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists". Bioorganic & Medicinal Chemistry Letters. 13 (14): 2369–72. doi:10.1016/s0960-894x(03)00403-7. PMID 12824036.
64. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (March 2005). "Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity". Bioorganic & Medicinal Chemistry Letters. 15 (5): 1467–70. doi:10.1016/j.bmcl.2004.12.080. PMID 15713408.
65. WO WO2007149728, Mohapatra S, Hellberg MR, Feng Z, "Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma", assigned to Alcon Manufacturing, Ltd.
66. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (January 2008). "Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity". Journal of Medicinal Chemistry. 51 (2): 305–13. doi:10.1021/jm0709034. PMID 18095642.
67. Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–27. doi:10.1021/jm301656h. PMID 23301527.
68. Sharif NA, McLaughlin MA, Kelly CR (February 2007). "AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist". Journal of Ocular Pharmacology and Therapeutics. 23 (1): 1–13. doi:10.1089/jop.2006.0093. PMID 17341144.
69. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA (January 2006). "1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity". Journal of Medicinal Chemistry. 49 (1): 318–28. doi:10.1021/jm050663x. PMID 16392816.
70. Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. Page 187
71. Shireman BT, Dvorak CA, Rudolph DA, Bonaventure P, Nepomuceno D, Dvorak L, Miller KL, Lovenberg TW, Carruthers NI (March 2008). "2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT_2A antagonists". Bioorganic & Medicinal Chemistry Letters. 18 (6): 2103–8. doi:10.1016/j.bmcl.2008.01.090. PMID 18282705.
72. Westkaemper RB, Runyon SP, Bondarev ML, Savage JE, Roth BL, Glennon RA (September 1999). "9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT_2A receptor antagonist". European Journal of Pharmacology. 380 (1): R5-7. doi:10.1016/S0014-2999(99)00525-7. PMID 10513561.
73. Westkaemper RB, Glennon RA (June 2002). "Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands". Current Topics in Medicinal Chemistry. 2 (6): 575–98. doi:10.2174/1568026023393741. PMID 12052195. S2CID 23576058.
74. Peddi S, Roth BL, Glennon RA, Westkaemper RB (December 2003). "Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT_2A receptor antagonist". European Journal of Pharmacology. 482 (1–3): 335–7. doi:10.1016/j.ejphar.2003.09.059. PMID 14660041.
75. Runyon SP, Mosier PD, Roth BL, Glennon RA, Westkaemper RB (November 2008). "Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT_2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation". Journal of Medicinal Chemistry. 51 (21): 6808–28. doi:10.1021/jm800771x. PMC 3088499. PMID 18847250.
76. Wilson KJ, van Niel MB, Cooper L, Bloomfield D, O'Connor D, Fish LR, MacLeod AM (May 2007). "2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT_2A ligands". Bioorganic & Medicinal Chemistry Letters. 17 (9): 2643–8. doi:10.1016/j.bmcl.2007.01.098. PMID 17314044.
77. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (October 2001). "5-hydroxytryptamine2A receptor inverse agonists as antipsychotics". The Journal of Pharmacology and Experimental Therapeutics. 299 (1): 268–76. PMID 11561089.
78. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE (September 2004). "Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 943–51. doi:10.1124/jpet.104.066688. PMID 15102927. S2CID 12205122.
79. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, Prosser W, Shanahan W, Sanchez M, Chuang E, Roth T (December 2008). "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep. 31 (12): 1663–71. doi:10.1093/sleep/31.12.1663. PMC 2603489. PMID 19090322.
80. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE (May 2006). "Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 910–8. doi:10.1124/jpet.105.097006. PMID 16469866. S2CID 22681576.
81. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW (August 2007). "ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models". The Journal of Pharmacology and Experimental Therapeutics. 322 (2): 862–70. doi:10.1124/jpet.107.121715. PMID 17519387. S2CID 28861527.
82. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD (October 2008). "A 5-HT_2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model". Pharmacology Biochemistry and Behavior. 90 (4): 540–4. doi:10.1016/j.pbb.2008.04.010. PMC 2806670. PMID 18534670.
83. Abbas A, Roth BL (December 2008). "Pimavanserin tartrate: a 5-HT_2A inverse agonist with potential for treating various neuropsychiatric disorders". Expert Opinion on Pharmacotherapy. 9 (18): 3251–9. doi:10.1517/14656560802532707. PMID 19040345. S2CID 71240383.
84. Office of the Commissioner (10 September 2019). "FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease". FDA.
85. Marek, G. J.; Martin-Ruiz, R.; Abo, A.; Artigas, F. (2005). "The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine". Neuropsychopharmacology. 30 (12): 2205–15. doi:10.1038/sj.npp.1300762. PMID 15886717. S2CID 12874315.
86. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (June 2007). "Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1054–61. doi:10.1124/jpet.106.117507. PMID 17337633. S2CID 11651502.
87. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (February 2007). "Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior". Neuron. 53 (3): 439–52. doi:10.1016/j.neuron.2007.01.008. PMID 17270739. S2CID 16309730.
88. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I (October 2008). "Agonist-directed trafficking of signalling at serotonin 5-HT_2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells". European Journal of Pharmacology. 594 (1–3): 32–8. doi:10.1016/j.ejphar.2008.07.040. PMID 18703043.
89. Schmid CL, Raehal KM, Bohn LM (January 2008). "Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo". Proceedings of the National Academy of Sciences of the United States of America. 105 (3): 1079–84. doi:10.1073/pnas.0708862105. PMC 2242710. PMID 18195357.
90. Abbas A, Roth BL (January 2008). "Arresting serotonin". Proceedings of the National Academy of Sciences of the United States of America. 105 (3): 831–2. Bibcode:2008PNAS..105..831A. doi:10.1073/pnas.0711335105. PMC 2242676. PMID 18195368.
91. Zhang G, Cheng J, McCorvy JD, Lorello PJ, Caldarone BJ, Roth BL, Kozikowski AP (July 2017). "Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications". Journal of Medicinal Chemistry. 60 (14): 6273–6288. doi:10.1021/acs.jmedchem.7b00584. PMC 7374938. PMID 28657744.
92. Bonis J, Furlong LI, Sanz F (October 2006). "OSIRIS: a tool for retrieving literature about sequence variants". Bioinformatics. 22 (20): 2567–9. doi:10.1093/bioinformatics/btl421. PMID 16882651. Supplementary material to article
93. Goldstein AT, Pukall C, Goldstein IL (2020). "Fibromyalgia and Female Sexual Pain Disorders". Female Sexual Pain Disorders: Evaluation and Management (2 ed.). Wiley. ISBN 978-1119482666.
94. Chee IS, Lee SW, Kim JL, Wang SK, Shin YO, Shin SC, Lee YH, Hwang HM, Lim MR (September 2001). "5-HT_2A receptor gene promoter polymorphism -1438A/G and bipolar disorder". Psychiatric Genetics. 11 (3): 111–4. doi:10.1097/00041444-200109000-00001. PMID 11702051. S2CID 39214172.
95. Choi MJ, Lee HJ, Lee HJ, Ham BJ, Cha JH, Ryu SH, Lee MS (2004). "Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene". Neuropsychobiology. 49 (1): 38–41. doi:10.1159/000075337. PMID 14730199. S2CID 19528052.
96. Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ (May 1996). "Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group". Lancet. 347 (9011): 1294–6. doi:10.1016/s0140-6736(96)90939-3. PMID 8622505. S2CID 8510590.
97. Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L, Carballo JJ, Saiz-Ruiz J, Fernandez-Piqueras J, Baldomero EB, de Leon J, Oquendo MA (July 2008). "Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 147B (5): 645–9. doi:10.1002/ajmg.b.30642. PMID 18163387. S2CID 31504282.
98. Gene Overview of All Published Schizophrenia-Association Studies for HTR2A Archived 21 February 2009 at the Wayback Machine – SzGene database at Schizophrenia Research Forum.
99. Serretti A, Drago A, De Ronchi D (2007). "HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies". Current Medicinal Chemistry. 14 (19): 2053–69. doi:10.2174/092986707781368450. PMID 17691947.
100. Laje G, McMahon FJ (December 2007). "The pharmacogenetics of major depression: past, present, and future". Biological Psychiatry. 62 (11): 1205–7. doi:10.1016/j.biopsych.2007.09.016. PMID 17949692. S2CID 37225993.
101. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (December 1991). "Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats". Journal of Nuclear Medicine. 32 (12): 2266–72. PMID 1744713.
102. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L (1996). "[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography". Life Sciences. 58 (10): PL 187–92. doi:10.1016/0024-3205(96)00013-6. PMID 8602111.
103. Johansen A, Hansen HD, Svarer C, Lehel S, Leth-Petersen S, Kristensen JL, Gillings N, Knudsen GM (January 2017). "The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [11C]Cimbi-36 labeled in two positions". Journal of Cerebral Blood Flow and Metabolism. 38 (4): 659–668. doi:10.1177/0271678x17746179. PMC 5888860. PMID 29215308.
104. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ (February 2004). "Decreased hippocampal 5-HT_2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography". Biological Psychiatry. 55 (3): 217–24. doi:10.1016/j.biopsych.2003.08.015. PMID 14744461. S2CID 24849671.
105. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L (November 1996). "Visualisation of loss of 5-HT_2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging". Psychiatry Research. 68 (1): 11–22. doi:10.1016/S0925-4927(96)02806-5. PMID 9027929. S2CID 32317795.
106. Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST (November 1998). "Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction". Brain Research. 813 (1): 167–71. doi:10.1016/S0006-8993(98)00909-3. PMID 9824691. S2CID 21884218.
107. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, Madsen K, Frøkjaer V, Martiny L, Paulson OB, Knudsen GM (March 2004). "A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables". NeuroImage. 21 (3): 1105–13. doi:10.1016/j.neuroimage.2003.10.046. PMID 15006678. S2CID 24403109.

Further reading

• Perez-Aguilar JM, Shan J, LeVine MV, Khelashvili G, Weinstein H (November 2014). "A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2". Journal of the American Chemical Society. 136 (45): 16044–54. doi:10.1021/ja508394x. PMC 4235374. PMID 25314362.

External links

• "5-HT_2A". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
• _2A%20Receptor 5-HT_2A+Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
• Human HTR2A genome location and HTR2A gene details page in the UCSC Genome Browser.
• Overview of all the structural information available in the PDB for UniProt: P28223 (5-hydroxytryptamine receptor 2A) at the PDBe-KB.